IRS 19 nasal spray 20ml №1

Name:
IRS 19 nasal spray in bottles of 20 ml in a pack. No. 1
Description:
A transparent, colorless, sometimes with a yellowish tinge, liquid with a slight odor of a flavor based on Nerol. Main active ingredient Bacteria lysates Release form Transparent, colorless, sometimes with a yellowish tint, liquid with a slight odor of flavoring agent based on Nerol. 100 ml active ingredients: bacterial lysates 43.27 ml composition of bacterial lysates: Streptococcus pneumoniae type I, II, III, V, VIII, XII 1.11 ml each Staphylococcus aureus ss aureus 9.99 ml Neisseria subflava 2.22 ml Neisseria perflava 2.22 ml Klebsiella pneumoniae ss pneumoniae 6.66 ml Moraxella catarrhalis 2.22 ml Haemophilus influenzae type B 3.33 ml Acinetobacter calcoaceticus 3.33 ml Enterococcus faecium 0.83 ml Enterococcus faecalis 0.83 ml Streptococcus pyogenes group A 1, 66 ml Streptococcus dysgalactiae group C 1.66 ml Streptococcus group G 1.66 ml excipients: glycine – 4.25 g; sodium merthiolate – no more than 1.2 mg; flavoring based on Nerol (linalol, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol) – 12.5 mg; purified water – up to 100 ml in 20 ml bottles (60 doses); in a box 1 bottle. Dosage 20 ml per pack. No. 1 Special instructions When prescribing drugs based on bacterial lysates for the purpose of immunostimulation to patients with bronchial asthma, asthma attacks may occur. In this case, it is recommended to stop treatment and not take drugs of this class in the future. Precautions for use Spray bottle: – keep away from heat above 50 °C and from direct sunlight; – do not pierce the vial; – do not burn the vial, even if it is empty. Pharmacological action of IRS® 19 increases specific and nonspecific immunity. When spraying IRS® 19, a fine aerosol is formed that covers the nasal mucosa, which leads to the rapid development of a local immune response. Specific protection is due to locally formed antibodies of the class of secretory immunoglobulins type A (IgA), which prevent the fixation and reproduction of infectious agents on the mucosa. Nonspecific immunoprotection is manifested in an increase in the phagocytic activity of macrophages and an increase in the content of lysozyme. Pharmacokinetics The drug mainly acts in the upper respiratory tract; currently there are no data on the systemic absorption of the drug. Indications for use Prevention of chronic diseases of the upper respiratory tract and bronchi; treatment of acute and chronic diseases of the upper respiratory tract and bronchi (rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis), etc.; restoration of local immunity after influenza and other viral infections; preparation for planned surgical intervention on the ENT organs and in the postoperative period. Route of administration and doses Intranasally, by aerosol administration of 1 dose (1 dose = 1 short press of the sprayer). When spraying the drug, you need to keep the bottle in an upright position and do not throw your head back. For prevention in adults and children from 3 months of age (2-3 weeks before the expected rise in incidence) – 1 dose of the drug in each nasal passage 2 times a day for 2 weeks. For the treatment of acute and chronic diseases of the upper respiratory tract and bronchi: adults and children over 3 years old – 1 dose of the drug in each nasal passage 2-5 times a day; children from 3 months to 3 years – 1 dose of the drug in each nasal passage 2 times a day (after preliminary release from the mucous discharge). Treatment is carried out until the symptoms of infection disappear. To restore local immunity after influenza and other respiratory viral infections: adults and children – 1 dose of the drug in each nasal passage 2 times a day for 2 weeks. In preparation for a planned surgical intervention and in the postoperative period: adults and children – 1 dose of the drug in each nasal passage 2 times a day for 2 weeks (it is recommended to start the course of treatment 1 week before the planned surgical intervention). At the beginning of treatment, reactions such as sneezing and increased nasal discharge may occur. As a rule, they are of short duration. If these reactions take a severe course, the frequency of administration of the drug should be reduced or it should be canceled. If the drug is left for a long time without use, a drop of liquid may evaporate and the resulting crystals will clog the outlet of the nozzle. This phenomenon occurs most often when the nozzle is removed and placed in the packaging with the top end down next to the bottle, without first washing and drying it. When the nozzle is clogged, several clicks are made in a row so that the liquid can pass under the action of excess pressure. If this does not help, the nozzle is lowered for several minutes in warm water. Use during pregnancy and lactation Not recommended during pregnancy (data on the potential for teratogenic or toxic effects on the fetus are not available). Precautions The use of IRS 19® does not affect the psychomotor functions associated with driving a car or operating machines and mechanisms. Interaction with other drugs Cases of negative interaction with other drugs are unknown. In the event of the appearance of clinical symptoms of a bacterial infection, it is possible to prescribe antibiotics against the background of the continued use of IRS® 19. Contraindications Hypersensitivity to the drug or its components in history; autoimmune diseases. Composition 100 ml active substances: bacterial lysates 43.27 ml composition of bacterial lysates: Streptococcus pneumoniae type I, II, III, V, VIII, XII 1.11 ml each Staphylococcus aureus ss aureus 9.99 ml Neisseria subflava 2.22 ml Neisseria perflava 2.22 ml Klebsiella pneumoniae ss pneumoniae 6.66 ml Moraxella catarrhalis 2.22 ml Haemophilus influenzae type B 3.33 ml Acinetobacter calcoaceticus 3.33 ml Enterococcus faecium 0.83 ml Enterococcus faecalis 0.83 ml Streptococcus pyogenes group A 1, 66 ml Streptococcus dysgalactiae group C 1.66 ml Streptococcus group G 1.66 ml excipients: glycine – 4.25 g; sodium merthiolate – no more than 1.2 mg; flavoring based on Nerol (linalol, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol) – 12.5 mg; purified water – up to 100 ml in 20 ml bottles (60 doses); in a box 1 bottle. Overdose Cases of overdose are unknown. Side effects While taking IRS® 19, the following side effects may occur, both related and not related to the action of the drug. Skin reactions: in rare cases, hypersensitivity reactions (urticaria, angioedema) and skin erythema-like and eczema-like reactions are possible. From the ENT and respiratory organs: rarely – asthma attacks and cough. In rare cases, at the beginning of treatment, there may be an increase in body temperature (? 39 ° C) for no apparent reason, nausea, vomiting, abdominal pain, diarrhea, nasopharyngitis, sinusitis, laryngitis, bronchitis. Isolated cases of thrombocytopenic purpura and erythema nodosum have been described. If the above symptoms appear, it is recommended to consult a doctor. Storage conditions At a temperature not higher than 25 ° C (do not freeze). In a strictly upright position. Keep out of the reach of children. Buy IRS 19 nasal spray 20ml №1 Price for IRS 19 nasal spray 20ml №1 Instructions for use for IRS 19 nasal spray 20ml №1